A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Summary

The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Selinexor 60 mg

  Participants will receive selinexor 60 mg oral tablets QW.

• Drug
  Selinexor 40 mg

  Participants will receive selinexor 40 mg oral tablets QW.

• Drug
  Ruxolitinib

  Participants will receive ruxolitinib per local package insert.

• Drug
  Pacritinib

  Participants will receive pacritinib per local package insert. For countries where not approved, 200 mg twice daily is the starting dose.

• Drug
  Momelotinib

  Participants will receive momelotinib per local package insert.

Locations (70)